CapsoVision Announces Pricing of Initial Public Offering
Rhea-AI Summary
CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has announced the pricing of its initial public offering (IPO). The company is offering 5,500,000 shares of common stock at $5.00 per share.
Trading is set to commence on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The offering, expected to close on July 3, 2025, aims to raise approximately $27.5 million in gross proceeds before deducting underwriting costs and other expenses. The underwriters have a 30-day option to purchase up to 825,000 additional shares at the IPO price.
The Benchmark Company and Roth Capital Partners are serving as joint book-running managers for the offering, which will be conducted through a prospectus as part of an SEC-approved registration statement.
Positive
- Expected to raise $27.5 million in gross proceeds from the IPO
- Listing on a major exchange (Nasdaq Capital Market)
- 30-day option for underwriters to purchase additional 825,000 shares indicates confidence in demand
Negative
- Relatively small IPO size may limit institutional investor interest
- Low share price of $5.00 could suggest limited market valuation
Insights
CapsoVision's $27.5M IPO brings a commercial-stage medical imaging company to Nasdaq at $5.00 per share.
CapsoVision has announced the pricing of its initial public offering on the Nasdaq Capital Market. The company is offering 5,500,000 shares of common stock at $5.00 per share, with trading expected to commence on July 2, 2025, under the ticker symbol "CV." The offering should generate
The IPO structure includes a standard 30-day option granted to underwriters to purchase up to an additional 825,000 shares at the initial offering price. This overallotment provision, commonly known as a "greenshoe option," allows underwriters to stabilize the stock price following the initial listing.
As a commercial-stage company focusing on advanced imaging and AI technologies for capsule endoscopy solutions, CapsoVision has positioned itself at the intersection of medical device technology and artificial intelligence. The mid-tier investment banks The Benchmark Company and Roth Capital Partners are serving as joint book-running managers, which is consistent with the offering size.
The successful registration with the SEC (declared effective on July 1) represents an important milestone in the company's development, providing access to public capital markets. While this offering size is relatively modest compared to larger medical technology IPOs, it potentially provides CapsoVision with additional capital to support its existing commercial operations.
SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of
CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, are expected to be approximately
The Benchmark Company, LLC and Roth Capital Partners are acting as joint book-running managers for the offering.
A registration statement on Form S-1 relating to the shares was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025. The offering is being made only by means of a prospectus forming a part of such registration statement. Copies of the final prospectus, when available, may be obtained from The Benchmark Company, LLC, 150 East 58th Street, 17th Floor, New York, NY 10155, Attention: Prospectus Department, or by email at prospectus@benchmarkcompany.com
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the expected trading of CapsoVision’s common stock on the Nasdaq Capital Market and the anticipated closing of the offering. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions, the satisfaction of customary closing conditions related to the initial public offering, and other risks described in the Company’s registration statement on Form S-1 filed with the SEC. Forward-looking statements speak only as of the date of this press release, and CapsoVision undertakes no obligation to update or revise these statements, except as required by law.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Kevin Lundquist
Chief Financial Officer, CapsoVision, Inc.
kml@capsovision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231
FAQ
What is the IPO price for CapsoVision (NASDAQ: CV) stock?
When will CapsoVision (CV) stock start trading on Nasdaq?
How much money is CapsoVision (CV) raising in its IPO?
Who are the underwriters for CapsoVision's IPO?
What does CapsoVision (CV) company do?
